Prognostic value of clinical treatment score post-5 years (CTS5) and late relapse risk in hormone receptor-positive HER2-positive breast cancer in the North Central Cancer treatment group (NCCTG) N9831 (Alliance) and NSABP-B31 (NRG) trials
- Citation:
- Cancer Res vol 81 (4 Supplement) PS6-03
- Meeting Instance:
- SABCS 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3906
- Pharmas:
- Genentech
- Grants:
- U10CA180821, BCRF-19-161, U10CA180868 and U10CA180822 (NRG)
- Corr. Author:
- Authors:
- Tanmayi Pai Angelica Gil Yaohua Ma Zhuo Li Pooja Advani Alvaro Moreno-Aspitia Gerardo Colon-Otero Edith A. Perez Yan Asmann Katherine Pogue-Geile E.A. Thompson Saranya Chumsri
- Networks:
- LAPS-MN026, NY021, PR028
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- NCCTG-N9831, NSABP B-31
- Phases:
- 3
- Keywords: